Cingulate Inc. extended the trial period for Matthew N. Brams, its Executive Vice President and Chief Medical Officer, through December 31, 2026. The company disclosed the change in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. The extension was part of Amendment No. 2 to Brams' employment agreement with Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc. The amendment is effective as of January 1, 2026, though the report date is September 30, 2026. Under the new terms, Brams' full-time employment trial period, originally set to end on September 30, 2026, now concludes at the end of the year. The company noted that the description of the amendment is qualified by reference to the full text, which is filed as Exhibit 10.1 to the report. Shane J. Schaffer, Chief Executive Officer of Cingulate Inc., signed the report on October 2, 2026. Cingulate Inc. is incorporated in Delaware and maintains its principal executive offices in Kansas City, Kansas. The company's common stock and warrants are registered on the Nasdaq Capital Market under the symbols CING and CINGW, respectively.